Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D050197 | Atherosclerosis NIH | 0.71 |
| D002318 | Cardiovascular Diseases NIH | 0.17 |
| D012141 | Respiratory Tract Infections NIH | 0.16 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002621 | Atherosclerosis HPO | 0.71 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.17 |
| HP:0011947 | Respiratory tract infection HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
There is a lack of knowledge about how many children are infected with SARS-CoV-2, how often they are asymptomatic, and how long the immunity persists. The main purpose of this study is to measure antibodies to SARS-CoV-2, symptoms, and risk factors in a representative cohort of children and adolescents in the canton of Zurich, Switzerland, shortly after re-opening of the school system and thereafter. The study also investigates antibodies to SARS-CoV-2 in parents of the children and school personnel.
Description: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies in randomly selected 5- to 16-year-old population of school-children, their parents, and school personnel, after the peak phase of the first major wave shortly after re-opening of schools in the canton of Zürich, Switzerland.
Measure: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies Time: at inclusionDescription: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies in randomly selected 5- to 16-year-old population of school-children and school personnel after 4-5 after recruitement in the canton of Zürich, Switzerland.
Measure: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies Time: Month 4-5Description: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies in randomly selected 5- to 16-year-old population of school-children and school personnel after 8-9 months after recruitment in the canton of Zürich, Switzerland.
Measure: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies Time: Month 8-9Description: Presence of symptoms (from January 2020) suggestive of a common cold, influenza and similar upper respiratory tract infections prior to the first study visit.
Measure: Presence of self-reported symptoms Time: at inclusionDescription: Proportion of seropositive children reporting symptoms suggestive of a common cold, influenza and similar upper respiratory tract infections between January 2020 and first study visit.
Measure: Proportion of seropositive children reporting COVID-19 related symptoms from January 2020 Time: at inclusionDescription: Presence of symptoms (from January 2020) suggestive of a common cold, influenza and similar upper respiratory tract infections during the follow-up.
Measure: Presence of self-reported symptoms Time: within 9 months of follow-upDescription: Incidence of self-reported symptoms and SARS-CoV-2 infections after the first study visit in initially seropositive participants.
Measure: Incidence of symptoms in initially seropositive participants Time: within 9 months of follow-upDescription: Proportion of seronegative participants of the first investigation wave who will self-report symptoms and infection with SARS-CoV-2.
Measure: Proportion of participants, seronegative at inclusion, with symptoms in the follow-up Time: within 9 months of follow-upDescription: Potential personal (socioeconomic characteristics, health status, presence of infection in family, personal hygiene and social distancing measures) and school-level (implementation of informational, social distancing and hygiene measures at school) risk and preventive factors for SARS-CoV-2 infection prior to the study. Questionnaire includes HBSC and custom questions.
Measure: Presence of risk factors for infection at inclusion (assessment via custom questionnaire) Time: at inclusionDescription: Potential personal (socioeconomic characteristics, health status, presence of infection in family, personal hygiene and social distancing measures) and school-level (implementation of informational, social distancing and hygiene measures at school) risk and preventive factors for SARS-CoV-2 infection during the follow-up. Questionnaire includes HBSC and custom questions.
Measure: Presence of risk factors for infection during follow-up (assessment via custom questionnaire) Time: within 9 months of follow-upDescription: Changes in lifestyle during the lock-down, compared to prior to it: frequency and duration (in hours, daily) of physical activity, duration (in hours, daily) of sleep, duration of screen-based media-use (in hours, daily). This outcome is measured only in the children population.
Measure: Self-reported lifestyle changes of participants at inclusion Time: at inclusionDescription: Changes in lifestyle after the lock-down and school reopening, compared to during lock-down: frequency and duration (in hours, daily) of physical activity, duration (in hours, daily) of sleep, duration of screen-based media-use (in hours, daily). This outcome is measured only in the children population.
Measure: Self-reported lifestyle changes of participants during follow-up Time: within 9 months of follow-upDescription: Changes over the study time in mental well-being of the participants during and after the lock-down: frequency scale (never/rarely/sometimes/often/always) of self-reported stress, anxiety, self-confidence feelings in the last 7 days. This outcome is measured only in the children population.
Measure: Self-reported mental well-being (KINDL questionnaire) Time: within 9 months of follow-upDescription: Changes over the study time in mental well-being of the participants during and after the lock-down: frequency scale (daily/weekly/monthly/rarer) of self-reported sadness, anxiety and sleeping problems (HBSC questionnaire question on mental well-being). This outcome is measured only in the children population.
Measure: Self-reported mental well-being (HBSC questionnaire) Time: within 9 months of follow-upDescription: Changes over the study time in quality-of-life of the participants during and after the lock-down: frequency scale (never/rarely/sometimes/often/always) assessment of self-reported positive and negative social interactions with family, friends and in the school environment in the last 7 days. This outcome is measured only in the children population.
Measure: Self-reported quality of life (KINDL questionnaire) Time: within 9 months of follow-upDescription: Prevalence of clusters of seropositive children, adolescents, and school personnel within schools and classes at baseline.
Measure: Prevalence of seropositive SARS-Cov-2 clusters in schools at inclusion Time: at inclusionDescription: Incidence of clusters of seropositive children, adolescents, and school personnel within schools and classes during the follow-up.
Measure: Incidence of seropositive SARS-Cov-2 clusters in schools during the follow-up Time: within 9 months of follow-upDescription: Impact of the number of children/adolescents and school personnel at a specific period (baseline, at the second and third testing date) within a school or class to the subsequent seropositivity within the same group.
Measure: Change in seropositive participants within school or class, depending on the initial proportion of seropositive participants Time: within 9 months of follow-upDescription: Incidence of seropositive children and school personnel according to potential risk factors and preventive measures for SARS-CoV-2 infection within schools.
Measure: Effect of risk factors and preventive measures on SARS-CoV-2 infection incidence within schools Time: within 9 months of follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports